Fiskus W, Piel J, Collins MP, Hentemann M, et al. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor. Blood 2024 Feb 16:blood.2023022832. doi: 10.1182/blood.2023022832.
PMID: 38437498